Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search


Rockeby Announces R&D Appointments

Rockeby Announces R&D Appointments

Australia, 10 March 2005 Rockeby biomed Limited (ASX:RBY) today announced the following appointments in the company's R&D department located in Perth.

Dr John Warmington, Director of Research & Development at Rockeby biomed (Australia) Pty Ltd will relinquish his position and assume a consultancy role as Chief Scientist with immediate effect. Dr Warmington will remain as Executive Director of Rockeby biomed (Australia) Pty Ltd and as Non-Executive Director of Rockeby biomed Limited, the ASX listed company of the Rockeby biomed Group of Companies.

Dr Warmington was instrumental in the Research & Developmental phases of Rockeby's two products namely SysCan3(r), a multi-well Elisa based hospital test kit and CanDia5(r), the world's first and only blood-based professional point of care diagnostic test kit. Dr Warmington will continue to play an important role as Chief Scientist as the company continues to commercialize new diagnostic products in the future pipeline.

Dr David Capes Ph.D, Head, Product Development, Diagnostics Division at Rockeby biomed (Australia) Pty Ltd will be promoted to Vice President - Research & Development with immediate effect. Dr Capes, was previously Director of R&D (Asia-Pacific) with Becton Dickinson where he oversaw a staff of 35 and a multi-million dollar budget. He has more than 20 years' pharmaceutical industry experience.

Dr Capes played an important role in the last year in Rockeby's US FDA 510(k) application, the ISO and Quality Management System, and CE Mark certification processes that has enabled Rockeby to achieve ISO certification and CE Mark approval ahead of schedule.

Dr Capes will continue to conduct research and development activities in line with corporate strategies and carry out product development of new diagnostic products.

Rockeby biomed is an ASX-listed (ASX: RBY) biotechnology company engaged primarily in the research, development and marketing of products for the diagnosis and treatment of fungal infections in humans. The company's main market is that of in-vitro diagnostic testing which covers serology tests in hospitals as well as point-of-care products for use by consumers or health professionals operating outside hospitals.


© Scoop Media

Business Headlines | Sci-Tech Headlines


Voluntary Administration: Renaissance Brewing Up For Sale

Renaissance Brewing, the first local company to raise capital through equity crowdfunding, is up for sale after cash flow woes and product management issues led to the appointment of voluntary administrators. More>>


Approval: Northern Corridor Decision Released

The approval gives the green light to construction of the last link of Auckland’s Western Ring Route, providing an alternative route from South Auckland to the North Shore. More>>


Media Mega Merger: Full Steam Ahead For Appeal

New Zealand's two largest news publishers have confirmed they are committed to pursuing their appeal against the Commerce Commission's rejection of the proposal to merge their operations. More>>

Crown Accounts: $4.1 Billion Surplus

The New Zealand Government has achieved its third fiscal surplus in a row with the Crown accounts for the year ended 30 June 2017 showing an OBEGAL surplus of $4.1 billion, $2.2 billion stronger than last year, Finance Minister Steven Joyce says. More>>


Mycoplasma Bovis: One New Property Tests Positive

The newly identified property... was already under a Restricted Place notice under the Biosecurity Act. More>>

Accounting Scandal: Suspension Of Fuji Xerox From All-Of-Government Contract

General Manager of New Zealand Government Procurement John Ivil says, “FXNZ has been formally suspended from the Print Technology and Associated Services (PTAS) contract and terminated from the Office Supplies contract.” More>>